Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center

Table 1

Patient characteristics (n = 38).

Variables	Median (range)/n (%)
Age (years)	54 (34–74)
Sex (male/female)	30 (78.9%)/8 (21.1%)
Etiology (HBV/others)	38 (100%)/0
ECOG score (0/1)	26 (68.4%)/12 (31.6%)
AFP (>400 ng/mL)	27 (71.1%)
Child–Pugh class (A/B)	35 (92.1%)/3 (7.9%)
Vascular invasion	27 (71.1%)
Extrahepatic metastasis	25 (65.8%)

HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein.